Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Withdraws India Patent Request For Already-Marketed Forteo (India)

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly withdrew a patent request in India for its new-generation biotech drug, Forteo (teriparatide recombinant human) in crystal form for treating osteoporosis. The U.S. company lost an earlier claim for a patent for the $600 million drug in another form when it faced opposition from USV. Lilly already had begun selling the drug in India as the only biotech drug for the disease, with the assumption it would soon have patent protection. USV and at least one other company are expected to launch generics as a result of the patent withdrawal. (Click here for more )
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel